CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
Tarun Kadaru, Amal Shibli-Rahhal
jbm. 2021;28(1):51-58.   Published online February 28, 2021
DOI: https://doi.org/10.11005/jbm.2021.28.1.51

Excel Download

Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
Journal of Bone Metabolism. 2021;28(1):51-58   Crossref logo
Link1 Link2 Link3

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
Journal of the Endocrine Society. 2020;4(Supplement_1):   Crossref logo
Link1 Link2

Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases
Bone Cancer. 2015;685-689   Crossref logo
Link1 Link2

Denosumab after bone progression with zoledronic acid: a single center experience
Annals of Oncology. 2015;26:vi122   Crossref logo
Link1 Link2 Link3

Zoledronic Acid Infusions Cut Treatment-Related Bone Loss
Ob.Gyn. News. 2008;43(5):15   Crossref logo
Link1 Link2

Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study
Journal of Bone and Mineral Research. 2017;32(3):611-617   Crossref logo
Link1 Link2 Link3

Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases: Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid
Breast Diseases: A Year Book Quarterly. 2013;24(3):220-221   Crossref logo
Link1 Link2

Letter to the Editor Regarding “Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial”
Journal of Bone and Mineral Research. 2021;   Crossref logo
Link1 Link2 Link3

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
Yearbook of Urology. 2011;2011:74-75   Crossref logo
Link1 Link2

Zoledronic acid cost effective in preventing AI-associated bone loss
PharmacoEconomics & Outcomes News. 2008;564(1):1-1   Crossref logo
Link1 Link2 Link3